From: Prognostic role of CD44 expression in osteosarcoma: evidence from six studies
Expression of CD44 (n) | OS/RFS (%) | Metastasis (n) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Study | Year | Age (median) | No. of patients | Method | CD44 cut-off | Positive | Negative | CD44 (+) | CD44 (-) | CD44 (+) | CD44 (-) |
Boldrini et al. [19] | 2010 | 15.9 | 34 | IHC | ≥10% | 17 | 17 | 21.5% | 25.3% | NA | NA |
Deng et al. [20] | 2013 | 18.3 | 90 | IHC | ≥25% | 59 | 31 | NA | NA | 38 | 12 |
Gvozdenovic et al. [21] | 2013 | NA | 53 | IHC | NA | 9 | 44 | NA | NA | 4 | 15 |
Kim et al. [22] | 2002 | 17 | 50 | IHC | ≥50% | 10 | 40 | NA | NA | 4 | 22 |
Kuryu et al. [23] | 1999 | 19 | 39 | IHC | ≥10% | 18 | 21 | 24% | 58% | 13 | 10 |
Ma et al. [24] | 2011 | 16 | 63 | IHC | NA | 62 | 1 | 40.3% | 0% | 12 | 0 |